SRX Global (NYSE American: SRXH) announced that it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company developing intranasal neuroscience therapies based on its proprietary pherine platform. SRX said the investment aligns with its strategy of creating long-term shareholder value through investments in high-conviction operating companies and strategic assets.
SRX said it believes Vistagen shares are undervalued and intends to engage constructively with the company’s leadership team and board of directors to discuss opportunities to unlock shareholder value.
To view the full press release, visit https://ibn.fm/NEczV
Questions around this news
What has SRX Global said it plans to do after acquiring a stake in Vistagen?
SRX Global says it plans to speak with Vistagen’s executives and board about possible ways to increase shareholder value. The release also presents the investment as part of SRX Global’s broader approach to investing in operating businesses and strategic assets. It does not provide details about the size or terms of the stake.
What therapies is Vistagen developing?
The release describes Vistagen as a biopharmaceutical company in a late clinical-development phase. It says the company is working on neuroscience therapies delivered through the nose and based on its pherine platform. The release does not identify specific therapies or provide details about their development status beyond that general description.
What does “clinical-stage” mean for a biopharmaceutical company?
A clinical-stage company is testing one or more potential treatments in studies involving people. These studies are intended to assess matters such as safety and whether a treatment may have a beneficial effect. Clinical-stage status does not mean a treatment has been approved or is available for routine use; the development process may continue through further testing and regulatory review.
How are intranasal therapies administered?
Intranasal therapies are given through the nose, often as a spray or another formulation placed inside the nasal passages. Depending on the medicine and its design, it may act locally in the nose or be absorbed into the body. The delivery method alone does not determine how well a therapy works or what conditions it can treat.
About SRX Global Inc.
SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.
For more information on the company, please visit: www.SRXGlobalInc.com
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Terms explained
- Biopharmaceutical
- A medicine developed using biological materials or processes, such as cells, proteins, or genetic techniques.
- Clinical-stage
- A phase of drug development in which a potential treatment is being studied in people.
- Intranasal
- Administered through or into the nose.
- Capital allocation
- The process of deciding how an organization will distribute its financial resources among investments, operations, and other uses.
- Shareholder value
- The financial benefit a company aims to create for people who own its shares.
